Literature DB >> 21740663

A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools.

H-H Lin1, I Langley, R Mwenda, B Doulla, S Egwaga, K A Millington, G H Mann, M Murray, S B Squire, T Cohen.   

Abstract

Efforts to stimulate technological innovation in the diagnosis of tuberculosis (TB) have resulted in the recent introduction of several novel diagnostic tools. As these products come to market, policy makers must make difficult decisions about which of the available tools to implement. This choice should depend not only on the test characteristics (e.g., sensitivity and specificity) of the tools, but also on how they will be used within the existing health care infrastructure. Accordingly, policy makers choosing between diagnostic strategies must decide: 1) What is the best combination of tools to select? 2)Who should be tested with the new tools? and 3)Will these tools complement or replace existing diagnostics? The best choice of diagnostic strategy will likely vary between settings with different epidemiology (e.g., levels of TB incidence, human immunodeficiency virus co-infection and drug-resistant TB) and structural and resource constraints (e.g., existing diagnostic pathways, human resources and laboratory capacity). We propose a joint modelling framework that includes a tuberculosis (TB) transmission component (a dynamic epidemiological model) and a health system component (an operational systems model) to support diagnostic strategy decisions. This modelling approach captures the complex feedback loops in this system: new diagnostic strategies alter the demands on and performance of health systems that impact TB transmission dynamics which, in turn, result in further changes to demands on the health system. We demonstrate the use of a simplified model to support the rational choice of a diagnostic strategy based on health systems requirements, patient outcomes and population-level TB impact.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740663     DOI: 10.5588/ijtld.11.0062

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  19 in total

1.  Computational models for neglected diseases: gaps and opportunities.

Authors:  Elizabeth L Ponder; Joel S Freundlich; Malabika Sarker; Sean Ekins
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

2.  The impact of new tuberculosis diagnostics on transmission: why context matters.

Authors:  Hsien-Ho Lin; David Dowdy; Christopher Dye; Megan Murray; Ted Cohen
Journal:  Bull World Health Organ       Date:  2012-07-16       Impact factor: 9.408

3.  Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis.

Authors:  Marco Schito; Trevor F Peter; Sean Cavanaugh; Amy S Piatek; Gloria J Young; Heather Alexander; William Coggin; Gonzalo J Domingo; Dennis Ellenberger; Eugen Ermantraut; Ilesh V Jani; Achilles Katamba; Kara M Palamountain; Shaffiq Essajee; David W Dowdy
Journal:  J Infect Dis       Date:  2012-03-29       Impact factor: 5.226

4.  Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions.

Authors:  Ivor Langley; Basra Doulla; Hsien-Ho Lin; Kerry Millington; Bertie Squire
Journal:  Health Care Manag Sci       Date:  2012-06-07

Review 5.  Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Authors:  William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

6.  Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis.

Authors:  Nicola Foster; Lucy Cunnama; Kerrigan McCarthy; Lebogang Ramma; Mariana Siapka; Edina Sinanovic; Gavin Churchyard; Katherine Fielding; Alison D Grant; Susan Cleary
Journal:  PLoS One       Date:  2021-05-14       Impact factor: 3.752

Review 7.  How can mathematical models advance tuberculosis control in high HIV prevalence settings?

Authors:  R M G J Houben; D W Dowdy; A Vassall; T Cohen; M P Nicol; R M Granich; J E Shea; P Eckhoff; C Dye; M E Kimerling; R G White
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

8.  Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling.

Authors:  D W Dowdy; R Houben; T Cohen; M Pai; F Cobelens; A Vassall; N A Menzies; G B Gomez; I Langley; S B Squire; R White
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

Review 9.  Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies.

Authors:  Alice Zwerling; Sourya Shrestha; David W Dowdy
Journal:  Adv Med       Date:  2015-03-15

10.  CAHRD Consultation 2014: the 10-20 year Horizon Introduction and Overview - as circulated to Consultation participants.

Authors:  S B Squire
Journal:  BMC Proc       Date:  2015-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.